Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer

Clinically Localized Prostate Cancer: AUA/ASTRO Guideline, Part I: Introduction, Risk Assessment, Staging and Risk-Based Management

(2022) James A. Eastham et al.   JOURNAL OF UROLOGY

Trends in Incidence of Metastatic Prostate Cancer in the US

(2022) Mihir M. Desai et al.   JAMA Network Open

Spatially resolved clonal copy number alterations in benign and malignant tissue

(2022) Andrew Erickson et al.   NATURE

Intermediate clinical endpoints for surrogacy in localised prostate cancer: an aggregate meta-analysis

(2021) Laila A Gharzai et al.   LANCET ONCOLOGY

Annual Report to the Nation on the Status of Cancer, Part 1: National Cancer Statistics

(2021) Farhad Islami et al.   JNCI-Journal of the National Cancer Institute

The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression

(2020) Richard J. Bryant et al.   BJU INTERNATIONAL

Radical Prostatectomy or Observation for Clinically Localized Prostate Cancer: Extended Follow-up of the Prostate Cancer Intervention Versus Observation Trial (PIVOT)

(2020) Timothy J. Wilt et al.   EUROPEAN UROLOGY

Prostate Cancer Incidence 5 Years After US Preventive Services Task Force Recommendations Against Screening

(2020) Ahmedin Jemal et al.   JNCI-Journal of the National Cancer Institute

Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT

(2020) Freddie C Hamdy et al.   HEALTH TECHNOLOGY ASSESSMENT

The Cambridge Prognostic Groups for improved prediction of disease mortality at diagnosis in primary non-metastatic prostate cancer: a validation study

(2018) V. J. Gnanapragasam et al.   BMC Medicine

Screening for Prostate Cancer

(2018) et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial

(2018) Jenny L. Donovan et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY

Radical Prostatectomy or Watchful Waiting in Prostate Cancer — 29-Year Follow-up

(2018) Anna Bill-Axelson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Active Surveillance Versus Treatment of Prostate Cancer: Should Metastasis Be the Primary End Point?

(2017) Anthony V. D’Amico   JOURNAL OF CLINICAL ONCOLOGY

Improved outcomes and precision medicine come within reach

(2017) Cora N. Sternberg et al.   Nature Reviews Urology

Radiotherapy for Prostate Cancer: is it ‘what you do’ or ‘the way that you do it’? A UK Perspective on Technique and Quality Assurance

(2016) M.D. Mason et al.   CLINICAL ONCOLOGY

Treatment or Monitoring for Early Prostate Cancer

(2016) Anthony V. D’Amico   NEW ENGLAND JOURNAL OF MEDICINE

10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer

(2016) Freddie C. Hamdy et al.   NEW ENGLAND JOURNAL OF MEDICINE

Standardisation of information submitted to an endpoint committee for cause of death assignment in a cancer screening trial – lessons learnt from CAP (Cluster randomised triAl of PSA testing for Prostate cancer)

(2015) Naomi J Williams et al.   BMC Medical Research Methodology

Analysis of the genetic phylogeny of multifocal prostate cancer identifies multiple independent clonal expansions in neoplastic and morphologically normal prostate tissue

(2015) Colin S Cooper et al.   NATURE GENETICS

Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial

(2014) J Athene Lane et al.   LANCET ONCOLOGY

Development of a complex intervention improved randomization and informed consent in a randomized controlled trial

(2008) Jenny L. Donovan et al.   JOURNAL OF CLINICAL EPIDEMIOLOGY